Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics
Maryam Samareh Salavatipour, Shirin Tavakoli, Aram Halimi, Shima Tavoosi, Amir-Hossein Baghsheikhi, Abdolkarim Talebi-Taheri, Mehdi Niloufari, Zahra Salehi, Javad Verdi, Soheila Rahgozar, Alireza Mosavi-Jarrahi, Mohammad Ahmadvand · 2024
Read Ubiquitin-specific peptidases in lymphoma: a path to novel therapeutics by Maryam Samareh Salavatipour, Shirin Tavakoli, Aram Halimi, Shima Tavoosi, Amir-Hossein Baghsheikhi, Abdolkarim Talebi-Taheri, Mehdi Niloufari, Zahra Salehi, Javad Verdi, Soheila Rahgozar, Alireza Mosavi-Jarrahi, Mohammad Ahmadvand (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11632177.txt.
Description
Maryam Samareh Salavatipour and a large team of co-authors review in 2024 a family of enzymes as possible drug targets in lymphoma. These enzymes remove ubiquitin tags from proteins, which affects protein stability, location, and activity. Abnormal activity has been linked to cancer growth and spread.
Following standard review methods, the team selected twenty-three studies from major databases. Specific enzymes were tied to cell cycle control, cell death, and key signaling paths in lymphoma. Some also carry value for diagnosis or prognosis. The authors argue these enzymes offer a path to new treatments for this blood cancer.
Catalog record
| CREATOR | Maryam Samareh Salavatipour, Shirin Tavakoli, Aram Halimi, Shima Tavoosi, Amir-Hossein Baghsheikhi, Abdolkarim Talebi-Taheri, Mehdi Niloufari, Zahra Salehi, Javad Verdi, Soheila Rahgozar, Alireza Mosavi-Jarrahi, Mohammad Ahmadvand |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |